Prosecution Insights
Prosecution Insights
Tech Center 1700 • Art Units: 1615 1618 1628 1742 1793
This examiner grants 63% of resolved cases
Shirley V. Gembeh is a highly active examiner in Tech Center 1700 and Art Unit 1615, with 1640 resolved cases. The allowance rate is 63.2%, which is a moderate rate that suggests a fair chance of success for applicants. This rate indicates that more than half of the applications are eventually granted under this examiner's review.
The interview lift is 34.0%, which is a very high figure. This indicates that interviews are an extremely powerful tool for applicants to use when working with this examiner to secure an allowance. The substantial lift suggests that oral advocacy is far more effective than written correspondence alone in resolving issues and moving the application toward a grant.
The median days to allowance is 968. This duration is consistent with other examiners in the same tech center, representing a typical timeframe for patent prosecution of under three years. The combination of a moderate allowance rate and a very high interview lift makes oral advocacy a critical strategy for success.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18811452 | COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCER | Non-Final OA | Massachusetts Institute of Technology |
| 18705061 | DRY POWDER COMPOSITIONS COMPRISING EUKARYOTIC CELLS AND METHOD OF THEIR MANUFACTURE AND USE | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18827277 | AMORPHOUS FORM OF TETRACYCLIC COMPOUND | Non-Final OA | Chugai Seiyaku Kabushiki Kaisha |
| 18722400 | PROCESS FOR REMOVING MAKEUP FROM KERATIN FIBRES WHICH HAVE BEEN TREATED BEFOREHAND WITH A COMPOSITION COMPRISING A PHOTOCROSSLINKABLE POLYMER | Non-Final OA | L'OREAL |
| 18626281 | COMPOSITIONS AND METHODS FOR ALTERING THE COLOR OF HAIR | Non-Final OA | L'OREAL |
| 18846364 | METFORMIN NANOFORMULATIONS AND METHODS OF USE THEREOF | Non-Final OA | Board of Regents of the University of Nebraska |
| 18862311 | RIFAXIMIN AND N-ACETYL CYSTEINE FORMULATIONS | Non-Final OA | Cedars-Sinai Medical Center |
| 18871626 | HOLLOW SPHERICAL PARTICLES | Non-Final OA | Kyoto University |
| 18725470 | PHARMACEUTICAL DRY POWDER INHALATION FORMULATION | Final Rejection | Bayer Pharma Aktiengesellschaft |
| 18699871 | AN INJECTABLE POLYHYDROXYALKANOATE MICROSPHERE AND A PREPARATION METHOD THEREOF | Non-Final OA | BEIJING JOYINERA BIOMATERIAL TECHNOLOGY CO., LTD. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy